NCT06920498

A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.

A Multipart Phase 1 Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study With Single and Multiple Dose Escalation to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-07941944 in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is to learn about the safety and tolerability of the study medicine (called PF-07941944) in healthy participants. This study is seeking participants who: * Are male or female between the ages of 18 and 60 * Are generally healthy The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help the investigators determine if the study medicine is safe and well tolerated. Participants enrolled in Part 1 will take part in this study for approximately 4 months. Participants enrolled in Part 2 or Part 3 will take part in this study for approximately 2.5 months. Study visits will take place at the study clinic. The study team will also call participants once at the end of the study over the phone.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	PF-07941944	Oral formulation
DRUG	Placebo	Oral formulation
DRUG	Midazolam	Oral formulation

Timeline

• Start date: 2024-12-03
• Primary completion: 2025-06-19
• Completion: 2025-06-19
• First posted: 2025-04-09
• Last updated: 2025-07-17

Locations

1 site across 1 country: Belgium

Regulatory

• FDA-regulated drug study